The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Lilly King spent the last two days of her professional swimming career doing what she’s done so well for the last decade.

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...